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ABSTRACT
The multidrug resistance (MDR) phenotype is considered a major
cause of the failure of cancer chemotherapy. The acquisition of
MDR is usually mediated by the overexpression of drug efflux
pumps such as glycoprotein P (P-gp) or multidrug resistance-
related protein 1 (MRP1). Thus, the identification, validation, and
development of compounds that mitigate the MDR phenotype by
modulating the activity of these transport proteins is an important
yet elusive target. Here, we have addressed this issue and
screened an N-trialkylglycine-based combinatorial library com-
posed of 5120 compounds to search for modulators of the MDR
phenotype. The screening identified 20 trimers of N-alkylglycine
that increased the intracellular accumulation of daunomycin
(DNM) in drug-resistant L1210R tumor cells that overexpressed
the P-gp. These compounds seem to act as P-gp antagonists, as
evidenced by the augmentation of DNM accumulation in the
L1210P-gp cell line, a drug-sensitive L1210 cell stably expressing
the murine P-gp protein. Similarly, several of the active N-trialkyl-
glycines also produced an increment in DNM uptake in human
HL60R cells, which primarily express the MRP1 protein. Trialkyl-
glycines notably sensitized L1210R and HL60R tumor cells to
DNM with a potency that rivaled that of verapamil. These findings
provide new molecular scaffolds for the development of effective
chemosensitizers against the MDR phenotype that, in due turn,
could be used as adjuvant drugs in cancer chemotherapy.
A plethora of cancer chemotherapies are currently in clin-
ical practice. Most of these treatments fail because of the
acquisition of the multidrug resistance (MDR) phenotype by
tumors (Pastan and Gottesmann, 1987). Although the molec-
ular mechanisms underlying MDR are diverse, a major strat-
egy is through overexpression of energy-dependent, unidirec-
tional transmembrane drug efflux pumps (Ling, 1997;
Gottesman et al., 2002). The P-glycoprotein (P-gp) is a 170-
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kDa membrane protein that belongs to the ATP-binding cas-
sette family of transporters (Bellamy, 1996; Ling, 1997; Borst
and Elferink, 2002). This protein is proposed to function as
an ATP-dependent efflux pump for hydrophobic agents, thus
conferring resistance by reducing the intracellular concen-
tration of cytotoxic drugs (Bellamy, 1996). P-gp expression in
tumors in vivo is associated with poor overall prognosis and
response to chemotherapy partly because of the protein ca-
pacity to transport a broad range of compounds, including
anthracyclines, vinca alkaloids, and taxanes (Sharom, 1997).
Chemotherapeutically-induced expression of P-gp has been
well documented in tumors such as acute leukemia and
small-lung cancer, breast and ovarian cancer, head and neck
tumors, Kaposi sarcoma, and child neuroblastoma (Tan et
al., 2000).
In addition to P-gp, overexpression of a series of homolo-
gous proteins termed multidrug resistance-related proteins
(MRPs) that share many pharmacological properties with
P-gp have been discovered more recently (Cole et al., 1992;
Borst and Elferink, 2002). The MRP family is made up of
190-kDa membrane proteins encoded by several closely re-
lated genes in humans that show low sequence homology to
P-gp (Cole and Deeley, 1996). These proteins also contribute
to the MDR phenotype (Lautier et al., 1996). For instance,
MRP1 confers resistance to anthracyclines and vinca alka-
loids but not to taxanes (Tan et al., 2000). The MRP1 protein
is overexpressed in most non-P-gp-mediated multidrug-resis-
tant cells (Loe et al., 1996), although its presence is not
consistently found in tumors (Lee et al., 2004). Furthermore,
MRP1 may be also coexpressed with P-gp, enhancing the
drug resistance of tumors (Legrand et al., 1999). Other pro-
teins such as the breast cancer-resistant protein and the lung
resistance-related protein have been identified in MDR tu-
mors that do not express P-gp or MRP1 (Tan et al., 2000).
The central role of MDR in clinical oncology has prompted
the discovery and development of antagonists of these trans-
port proteins, specifically P-gp. These agents are known as
chemosensitizers or revertants of the MDR phenotype. By
antagonizing the active efflux of anticancer drugs, chemosen-
sitizers promote an accumulation of these drugs into the
tumor cells, thus augmenting the efficacy of the chemother-
apeutic treatment (Tan et al., 2000; Robert and Jarry, 2003).
The first generation of chemosensitizers consisted of calcium
channel blockers, calmodulin inhibitors, antibiotics, cardio-
vascular drugs, cyclosporins, and other compounds (Robert
and Jarry, 2003). Most of these agents exhibit side effects
that prevented their clinical development (Robert and Jarry,
2003). Chemical modification of these compounds led to the
identification of a new generation of chemosensitizers with
improved efficacy and lower, but still unacceptable, toxicity
(Robert and Jarry, 2003). The third generation of MDR an-
tagonists included molecules selected on the basis of struc-
tural features and then tested in vitro. This strategy led to
the identification, among others, of triazine piperidinyl com-
pounds, dihydropyrroquinolines, and anthranilic acid deriv-
atives (Robert and Jarry, 2003). Together, these discovery
efforts highlight the importance of developing inhibitors of
proteins involved in MDR as a therapeutic strategy to in-
crease the efficacy of current chemotherapy.
Here, we have aimed to identify new molecular scaffolds
that define chemosensitizing activity by screening a mixture-
based, N-trialkylglycine combinatorial library composed of
5120 compounds. We found a set of 20 trimers of N-alkyl-
glycines that antagonized P-gp function, expelling the an-
thracycline daunomycin (DNM) with an efficacy and potency
that rivaled that shown by verapamil (VRP), a well estab-
lished P-gp antagonist (Robert and Jarry, 2003). These com-
pounds also inhibited the MRP1 transporter, as evidenced by
their potent revertant activity on human HL60R. Cytotoxic-
ity studies unveiled that several trimers of N-alkylglycines
chemosensitized the MDR phenotype in DNM-resistant
L1210R and HL60R cells. Therefore, these results provide
new MDR modulators that, in due turn, may be developed as
clinically useful chemosensitizers.
Materials and Methods
Synthesis of Trialkylglycines-Based Combinatorial Mixtures
and Individual Compounds. An optimized library of 5120 peptoids
in 52 controlled mixtures was synthesized by using the positional scan-
ning format on solid phase. The mixture positions (X, Fig. 1) were
incorporated by coupling a mixture of 22 or 16 selected primary amines
with the relative ratios adjusted to yield equimolar incorporation (Hu-
met et al., 2003). Briefly, starting from Rink amide resin (0.7 mEq/g;
Rapp Polymere, Tuebingen, Germany), the eight-step synthetic path-
way involved the initial release of the Fmoc protecting group. Thereaf-
ter, the successive steps of acylation with chloroacetyl chloride followed
by the corresponding amination of the chloromethyl intermediate, using
the selected individual amine (O, Fig. 1) or the mixture of amines (X,
Fig. 1), was conducted. Thereafter, the products were released from the
resin by using a trifluoroacetic acid/dichloromethane/water cocktail,
solvents were evaporated, and the residues were lyophilized and dis-
solved in 10% dimethyl sulfoxide at a concentration of 5 mg/ml for
screening. Individual oligo N-alkylglycines were prepared by simulta-
neous multiple solid-phase synthesis following the same synthetic se-
quence. The purity and identity of the most active individual oligo
N-alkylglycine compounds were determined by analytical high-perfor-
mance liquid chromatography, mass spectometry, and 1H and 13C NMR
(see Supplemental Data).
Cell Cultures. DNM-resistant murine L1210R cells and human
promyelocytic (HL60R) leukemia cells were obtained by stepwise
selection of wild-type L1210 and HL60 with increasing DNM con-
centrations and maintained in cultures as previously described (Soto
et al., 1993; Castro-Galache et al., 2003). L1210P-gp cells are L1210
tumor cells that stably express the mouse mdr1a cDNA (Castro-
Galache et al., 2003). Cultures were maintained at 37°C in humidi-
fied 5% CO2 atmosphere (Castro-Galache et al., 2003).
Daunomycin Accumulation Assays. L1210R overexpressing
the P-gp and HL60R cells overexpressing the MRP1 were washed
once with Hepes saline buffer, and the pellet was resuspended in
Hepes saline buffer at 1  106/ml per sample. Thereafter, cells were
incubated with 3 M DNM (control) and 5 M VRP (as a reference of
chemosensitizing effect) or the peptoid mixtures (0.1 mg/ml) for 1 h
at 37°C. After incubation, steady-state intracellular DNM accumu-
lation was determined by flow cytometry as previously described
(Soto et al., 1993; Martı´n-Orozco et al., 2004).
In Vitro Proliferation Assays. In vitro proliferation assays com-
pared the growth rate of L1210 and L1210R cells and that of HL60
and HL60R cells by 3-(4,5-dimethylthiazo-2-yl)-2,5 diphenyltetrazo-
lium bromide (MTT; Sigma-Aldrich, St. Louis, MO) assay after plat-
ing 2  104 cells in a 96-well plate for 48 h. Cell plates were
incubated with increasing concentrations of DNM (0.01–25 M) in
the absence and presence of 5 M trialkylglycines or VRP. For the
viability assays, cell were washed extensively with phosphate-buff-
ered saline, and the MTT reagent was added to each well and
incubated for 4 h at 37°C. Thereafter, 100 l/well of acid-isopropyl
alcohol was added and mixed thoroughly to dissolve the dark blue
crystals, and plates were read on an enzyme-linked immunosorbent
assay reader using a wavelength of 570 nm. Data were normalized
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and plotted as a function of the DNM concentration and fitted to a
Michaelis-Menten isotherm to determine the concentration of DNM
that inhibits half-maximal cellular proliferation (IC50):
G
Gmax

1
1 DNMIC50 
nH
where G denotes growth at the different DNM concentrations, Gmax
indicates growth in the absence of DNM, and nH is the slope of the
isotherm. The degree of resistance to DNM was obtained as the ratio
of the IC50 values for the resistant and wild-type subline.
Modelingwith Catalyst. The computational molecular modeling
studies were carried out using a Silicon Graphics Octane worksta-
tion (SGI, Mountain View, CA). The three-dimensional structures of
the different ligands of P-gp [(R)-verapamil, rhodamine 123, vinblas-
tine, colchicine, and calcein acetoxymethyl ester] were built using
Catalyst version 4.7 (Accelrys, San Diego, CA). The number of con-
formers generated using the “best” feature of the program for each
inhibitor was limited to a maximum of 250 with an energy range of
20 kcal/mol. Using the common-features hypotheses function (Hip-
Hop) in Catalyst, 10 hypotheses were generated using the above
conformers for each of the training set molecules. The eventual
protonation of these molecules at the physiological pH and selected
features for the inhibitors such as hydrogen bond donor, hydrogen
bond acceptor, and hydrophobic and ring aromatic, were considered.
After assessing the 10 hypotheses generated, the pharmacophore
hypothesis with the lowest energy cost was selected. Selected N-
trialkylglycines and tariquidar, a potent and specific antagonist of
P-gp (Mistry et al., 2001), were fitted into the selected hypothesis.
The correct alignment was used with the best-fit procedure to assess
how all conformers from both peptoids might orient within the hy-
pothesis, minimizing the distance between the center of the hypoth-
esis features and their mapping to atoms on the molecule.
Results
Screening of a N-Trialkylglycine-Based Combinato-
rial Library to Identify Novel MDR Modulators. A fo-
cused, mixture-based combinatorial library made of trimers
of N-alkylglycines in a positional scanning format was de-
signed and synthesized to identify antagonists of the P-gp
protein. The library consisted of three separate positions,
each having a single position defined with one of the 20
(OXX) or 16 (XOX, XXO) primary amines used (Table 1), and
the remaining two positions had an equimolar mixture of
these amines. The rationale of using two different sets of
amines was due to side reactions that occur when primary
amines bearing an additional tertiary amino moiety were
used as diversity sources for the internal or/and C-terminal
positions of the trimer. Thus, none of the amines used in the
design of the library for the internal and C-end positions had
these additional amino groups, whereas four additional
amines containing the tertiary amino moiety were added to
the set used for the N-terminal position (Humet et al., 2003).
The library was organized as an array of 52 separate mix-
tures. Each mixture contained either 256 (OXX) or 320 mol-
ecules (XOX, XXO), and the library chemical diversity com-
prised 5120 individual trimers. The set of amines included
aliphatic and aromatic groups to increase the probability of
finding P-gp inhibitors, to enhance membrane permeability,
and to improve the bioavailability of the active N-trialkyl-
glycines.
Peptoid mixtures were assayed to find inhibitors of the
P-gp transporter. The assay was based on the observation
that accumulation of the fluorescent cytostatic drug DNM in
L1210R cells, a tumor cell line that overexpresses P-gp (see
Supplemental Data), is enhanced in the presence of P-gp
antagonists such as verapamil (Robert and Jarry, 2003).
Changes in the intracellular accumulation of DNM are
readily followed by flow cytometry, thus providing a sensitive
and reliable assay for seeking tumor-resistant chemosensi-
tizers (Soto et al., 1993; Nelson et al., 1998; Schwab et al.,
2003). Cellular fluorescence was determined after 2 h of
Fig. 1. Screening of an oligo N-substituted glycine combinatorial library to
identify chemosensitizers of L1210R tumor cells. A–C, DNM intracellular
accumulation profile of the 52 library mixtures. Each graph represents the
effect on the accumulation of the anthracycline for each of the three positions
that compose the library. A1 through A20 refers to the amine number
present in Table 1. The bars denote the activity of each mixture as a function
of the number of the defined amine used to generate the chemical diversity.
Library mixtures were assayed at 100 g/ml, and those selected positive
were assayed at 50 g/ml. None, intracellular accumulation of anthracycline
in L1210R in the absence of chemosensitizers. VRP refers to the DNM
accumulation in the presence of 5 M of compound. Cells were incubated
with different mixtures for 1 h at 37°C and thereafter exposed to 3 M DNM
for an additional 1 h at 37°C. Intracellular accumulation of DNM was
monitored by flow cytometry. O, defined position in the chemical library; X,
combinatorialized position with an equimolar mixture of the amines used.
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incubation in the presence of the peptoid mixtures at a con-
centration of 100 g/ml. As illustrated in Fig. 1A, six of the
peptoid mixtures that had the first position defined increased
the accumulation of DNM to an extent similar to that of 5 M
VRP. The number of positive mixtures was eight for the
second position (Fig. 1B) and seven for the third (Fig. 1C).
Together, the assay identified a total of 336 peptoids as
potential modulators of the MDR phenotype. To isolate the
most effective chemistries at the three positions of the tri-
mer, we assayed the positive mixtures at 50 g/ml for in-
creased DNM cellular accumulation. Figure 1, A through C,
shows that amines A3, A7, A10, A15, and A16 were preferred
at R1, whereas aromatic amines A12 and A14 were selected
for the R2 and R3 positions (see Table 1 for structures). The
selection of these amines was considered based on both the
high activity that restored DNM intracellular accumulation
and lack of cytotoxicity at 50 g/ml.
When used in concert, the data derived from the screening
suggest the chemical identity of the bioactive N-trialkylgly-
cines in the library (Garcı´a-Martı´nez et al., 2002; Humet et
al., 2003). Thus, a family of 20 individual N-trialkylglycines,
resulting from all possible combinations of the active func-
tional groups identified in the deconvolution process, was
synthesized. The increase in DNM accumulation in L1210R
cells produced by all N-alkylglycines (5 M) is depicted in
Fig. 2A. Notice that these peptoids did not affect the accu-
mulation of DNM in L1210 cells (Fig. 2B), consistent with an
effect on the MDR phenotype. Several of the compounds
displayed a potency in intracellular drug accumulation sim-
ilar to VRP. In particular, peptoids N151212C and N161212C
exhibited a remarkable revertant activity on L1210R cells.
The dose-response relationship for these N-trialkylglycines
shows an IC50 of 3.5  2.1 M for N151212C (Fig. 2C); for
N161212C, a value of 4.3  1.9 M was obtained. Both
compounds also inhibited the extrusion of the cationic dye
rhodamine 123 from L1210R cells (see Supplemental Data).
These results indicate that identified N-trialkylglycines are
chemosensitizers of the MDR phenotype, presumably by in-
hibiting the P-gp drug transporter.
Active N-Trialkylglycines Seem to Be P-gp Antago-
nists. To investigate whether active peptoids act on the P-gp
protein, we used the L1210P-gp cell line, which is made up of
DNM-sensitive L1210 cells that stably express the murine
P-gp transporter cDNA (Castro-Galache et al., 2003). L1210P-gp
cells show a reduced intracellular accumulation of DNM com-
pared with untransfected L1210 cells (Fig. 3A). The extent of
drug accumulation in L1210P-gp is akin to that exhibited by
DNM-resistant L1210 cells, including the sensitivity to VRP
(Fig. 3A). Unlike L1210R cells, however, the L1210P-gp cell line
does not exhibit a drug-induced pleiotropic phenotype, thus
allowing a determination of whether newly identified chemo-
sensitizers act as P-gp antagonists. The activity of the 20 iden-
tified N-trialkylglycines on DNM accumulation in L1210P-gp
cells is displayed in Fig. 3B. It is noteworthy that the most
active peptoids in L1210R cells, N151212C and N161212C,
were also the most potent in increasing DNM accumulation in
L1210P-gp. Dose-response curves indicate that peptoids
N151212C and N161212C exhibit a similar inhibitory efficacy
(IC50) as that obtained in L1210R cells (data not shown). There-
TABLE 1
Set of amines used for the synthesis of the N-trialkylglycine-based combinatorial library
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fore, these results imply that active peptoids are inhibitors of
the P-gp protein that is overexpressed in L1210R cells.
Identified N-Trialkylglycines Chemosensitize L1210R
Cells to DNM Cytotoxicity. We next characterized the che-
mosensitizing activity of the N-trialkylglycines N151212C and
N161212C in DNM cytotoxicity assays in L1210R tumor cells.
For this task, L1210 and L1210R cells were incubated with
increasing concentrations of the anthracycline in the absence
and presence of 5 M of the two most active peptoids. As a
Fig. 2. Identified N-trialkylglycines increase the intracellular accumula-
tion of DNM in L1210R cells. Representative activity of N-alkylglycine
trimers tested at 5 M that augmented the cytosolic concentration of
DNM in L1210R (A) and L1210 (B) tumor cells. None, intracellular
accumulation of anthracycline in L1210R in the absence of chemosensi-
tizers. VRP refers to the DNM accumulation in the presence of 5 M
verapamil. C, dose-response relationship for the activity of compound
N151212C that augmented the cytosolic accumulation of DNM in L1210R
cells. The solid line depicts the best fit to a Michaelis-Menten isotherm.
The concentration of DNM that inhibits the half-maximal cellular prolif-
eration (IC50) value was 3.5  2.1 M. Data are mean  S.E.M., with n 
3. N-trialkylglycines are referred to as the amine number selected from
the N-to-C positions. Inset, molecular structure of peptoid N151212C.
Fig. 3. Identified N-trialkylglycines seem to act as antagonists of the
P-gp. A, L1210 cells stably expressing the human P-gp protein (L1210P-gp)
show a decrease in intracellular accumulation of DNM. The panel shows
the flow cytometry distribution peaks of cytosolic DNM in L1210P-gp (a),
L1210P-gp in the presence of 5 M VRP (b), and L1210 (c). B, represen-
tative profile of the potency exerted by 5 M N-trialkylglycines on the
cytosolic uptake of DNM in L1210P-gp. None, accumulation of anthracy-
cline in the absence of any compound or drug. VRP, intracellular concen-
tration of DNM in the presence of 5 M VRP. Cells were incubated with
different compounds for 1 h at 37°C and thereafter exposed to 3 M DNM
for an additional 1 h at 37°C. Intracellular accumulation of DNM was
monitored by flow cytometry.
116 Abad-Merin et al.
positive control, VRP (5 M)-induced chemosensitization of
L1210R cells was evaluated. Dose-response curves of DNM
cytotoxicity revealed a concentration of anthracycline that in-
hibits half-maximally the cellular proliferation (IC50) of 0.11 
0.03 and 20  2 M for L1210 cells and L1210R tumor cells,
which represents a degree of DNM resistance (DDR), calculated
as the ratio of the IC50 of L1210R with respect to that exhibited
by drug-sensitive L1210 cells, of 180 (Fig. 4A). The presence of
5 M VRP reduced the IC50 (6.0  0.1 M) of resistant cells
3-fold, leading to a DDR of 54. Similarly, 5 M of peptoids
N151212C and N161212C significantly decreased the DDR by
3-fold, from 180 to 45 (IC50  5.0  0.3 M) and 50 (IC50 
5.5  0.5 M), respectively (Fig. 4B). It is noteworthy that this
concentration of peptoids did not exhibit cytotoxicity, thus im-
plying that the chemosensitization of L1210R was due to a
direct inhibition of the P-gp pump activity. To further substan-
tiate this notion, reverse transcriptase-polymerase chain reac-
tion analysis of the MDR1 gene shows that the peptoids did not
affect the mRNA levels of P-gp in L1210R cells (see Supplemen-
tal Data). Thus, these results indicated that identified peptoids
are potent chemosensitizers of the P-gp-mediated MDR pheno-
type.
Identified N-Trialkylglycines Also Modulate the
MRP1 Transporter. The acquired MDR phenotype may be
mediated by overexpression of the P-gp protein or other
members of the ATP-binding cassette family of membrane
transporters such as the MRP1 protein (Tan et al., 2000). For
instance, human HL60 expressed the MRP1 protein upon
acquisition of the DNM-induced MDR phenotype (Ross et al.,
1996). Hence, we next questioned whether identified active
peptoids were also modulators of the resistant phenotype of
HL60 cells. To address this question, we determined the
potency of the 20 individual peptoids identified that aug-
mented the intracellular accumulation of DNM in HL60R
cells. Notably, most of the individual trimers of N-alkylgly-
cines increased the uptake of the anthracycline to an extent
that competed with that of VRP in HL60R cells (Fig. 5A) but
were innocuous to HL60 tumor cells (Fig. 5B). These results
indicate that identified peptoids are modulators of the MRP1
protein that is overexpressed in HL60R tumor cells. The
activity profile of these compounds in P-gp and MRP1 seems
rather similar, suggesting that they may interact with a
structurally homologous binding site.
Active Peptoids Chemosensitize HL60R Cells to
DNM. Because virtually all 20 trialkylglycines displayed a
comparable potency that augmented the intracellular con-
centration of DNM in HL60R tumor cells, we next evaluated
their chemosensitizing activity in cytotoxicity assays. Dose-
response relationships of the cellular viability at increasing
DNM concentrations reveal an IC50 of 0.25  0.03 M for
HL60 and 7.6  0.2 M for HL60R cells, indicating a degree
of DNM resistance of 30 (Fig. 6A). This value was decreased
up to 3-fold by 5 M VRP (IC50  3.1  0.1 M). Similarly,
the cytotoxicity of DNM to HL60R was notably augmented by
the presence of 5 M of the peptoids (Fig. 6B). All N-trialk-
ylglycines sensitized HL60R 3-fold to DNM cytotoxicity.
Note that, as for L1210R, the N-trialkylglycine N151212C
exhibited the highest chemosensitizing activity on HL60R
cells (IC50  2.1  0.2 M). Therefore, identified N-trialk-
ylglycines sensitize the MDR phenotype mediated by both
P-gp and MRP1 transporter proteins.
Molecular Model of N151212C. We used the Catalyst
software to study the fitting of peptoid N151212C into the
pharmacophore model generated from a set of different, well
established P-gp inhibitors and substrates that presumably
bind to the same site on the protein, such as (R)-verapamil,
rhodamine 123, vinblastine, colchicine, and calcein ace-
toxymethyl ester. These compounds generated a three-
dimensional pharmacophore model featuring the two hydro-
phobic groups (aromatic or aliphatic chains), one aromatic
ring, and two hydrogen bond acceptors, which is consistent
by the model reported by Ekins et al. (2002). Peptoid
N151212C was fit into the pharmacophoric model to deter-
mine whether the compound fulfilled similar properties. As
illustrated in Fig. 7A, the lowest energy conformation of
peptoid N151212C fit nicely with the pharmacophore. This
Fig. 4. N-trialkylglycines N151212C and N161212C decrease the degree
of resistance of L1210R cells. A, dose-response relationships of DNM
cytotoxicity on L1210S and L1210R in the absence and presence of che-
mosensitizers (5 M). Cell proliferation was determined by the MTT
method. Data are normalized with respect to the cellular growth in the
absence of cytostatic. Solid lines depict the best fit to a sigmoidal curve.
The concentration of DNM that inhibits half-maximal cellular prolifera-
tion (IC50) values were 0.11  0.03 M for L1012; 20  2 M for L1210R;
6.0  0.1 M for L1210R in the presence of VRP; 5.0  0.3 M for L1210R
in the presence of N151212C; and 5.5  0.5 M for L1210R in the
presence of N161212C. Values are given as mean  S.E.M., with n  3.
C, effect of the compounds on the resistant degree of L1210R. The extent
of DNM resistance was calculated as the ratio of DNM IC50 of L1210R
and the IC50 of drug-sensitive L1210 cells in the absence and/or presence
of peptoids or VRP.
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result is similar to that obtained with tariquidar, a potent
and specific inhibitor of P-gp currently in clinical trials (Mis-
try et al., 2001; Robert and Jarry, 2003), which lowest energy
conformation also shows an adequate alignment with the
model (Fig. 7B) and a good fitting with peptoid N151212C
(Fig. 7C). Thus, compound N151212C fulfills the structural
properties characteristics of chemosensitizers that antago-
nize the P-gp and MRP1 pump activities.
Discussion
MDR, the principal mechanism by which many cancers
develop resistance to anticancer drugs, is a major factor in
the failure of chemotherapy approaches (Pastan and Gottes-
mann, 1987; Ling, 1997). Resistance to therapy has been
correlated to the presence of at least two molecular pumps in
tumor cell membranes that actively expel chemotherapy
drugs from the cell interior, thus allowing tumors to avoid
the toxic effects of cytostatics. The two pumps commonly
found to confer chemoresistance to cancer cells are P-gp and
MRP1. Because of their importance, they are the targets of
several anticancer efforts, as evidenced by the number of
chemosensitizers that have been tested in preclinical and
clinical trials (Tan et al., 2000; Robert and Jarry, 2003).
However, most of these compounds have been discarded be-
cause of concerns of toxicity and/or unwanted side effects
(Robert and Jarry, 2003). The third generation of revertant
drugs may partially attenuate these concerns. These com-
pounds may be used as novel scaffolds that, in due turn, may
be developed into clinical chemosensitizers. Nonetheless, the
enormous challenge of finding chemosensitizers agents that
act as inhibitors of P-gp and MRP1 is still a fundamental
endeavor in cancer chemotherapy. Here, we have screened a
N-trialkylglycine-based library composed of 5120 compounds
Fig. 5. N-trialkylglycines increase the accumulation of DNM in HL60R
cells. Profile activity of 5 M N-trialkylglycines on the intracellular
accumulation of DNM on HL60R (A) and HL60 tumor cells (B). None,
accumulation of anthracycline in the absence of any compound or drug.
VRP, intracellular concentration of DNM in the presence of 5 M VRP.
Cells were incubated with different compounds for 1 h at 37°C and
thereafter exposed to 3 M DNM for an additional 1 h at 37°C. Intracel-
lular accumulation of DNM was monitored by flow cytometry.
Fig. 6. Trimers of N-alkylglycines chemosensitize HL60R cells that ex-
press the MRP1 protein. A, dose-response relationships of DNM cytotox-
icity on HL60 and HL60R in the absence and presence of 5 M chemo-
sensitizers. Solid lines depict the best fit to a sigmoidal curve. The IC50
values were 0.25  0.03 M for HL60; 6.4  0.5 M for HL60R; 3.1  0.2
M for HL60R in the presence of VRP; and 2.1  0.4 M for HL60R in the
presence of N151212C. Values are given as mean  S.E.M., with n  3.
B, activity profile of N-trialkylglycines on the resistant degree of HL60R.
The extent of DNM resistance was calculated as the ratio of DNM IC50 of
HL60R and the IC50 of HL60 cells in the absence and/or presence of
peptoids or VRP.
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to find antagonists of P-gp and MRP1. Trimers of N-alkyl-
glycines are a family of non-natural molecules that are at-
tractive for the drug discovery process because of their broad
variety of biological activities. They have been successfully
used for the identification of diverse activity, ranging from
high-affinity ligands for membrane receptors to disruptors of
macromolecular complexes (Heizmann et al., 1999; Humet et
al., 2003). Furthermore, N-trialkylglycines have been used to
identify anti-inflammatory, analgesic, and neuroprotectant
drugs that exhibit in vivo activity (Garcı´a-Martı´nez et al.,
2002; Montoliu et al., 2002; Planells-Cases et al., 2002).
Thus, the diverse activities associated with N-trialkylgly-
cines, along with their proteolytic resistance and in vivo
stability and low-to-moderate toxicity, make them good che-
mosensitizer candidates. The most salient contribution of
this study is the identification of a set of 20 trimers of N-
alkylglycines that selectively increase the intracellular accu-
mulation of DNM in cancer resistant cells. This activity
seems to be associated with the inhibition of the P-gp pump,
as indicated by the chemosensitizing activity of these mole-
cules in a cancer-sensitive line that stably expresses the
murine P-gp. It is noteworthy that the two most active com-
pounds antagonizing the activity of P-gp, N151212C and
N161212C, reduced the degree of resistance of L1210R cells
by 3-fold at a concentration that rivaled that of VRP. This
inhibition was partially reversible, as evidenced by the mod-
est effect on the intracellular accumulation of DNM of wash-
ing out the peptoids before incubation of the cytostatic (data
not shown). Furthermore, these 20 compounds also aug-
mented the intracellular accumulation of anthracycline in
human HL60R tumor cells that overexpress the MRP1 pump.
Notice that virtually all of the N-trialkylglycines identified in
the screening modulated MRP1 activity to an analogous or
higher extent than VRP. This observation is further substan-
tiated in the DNM cytotoxicity assays where all the peptoids
decrease the degree of resistance of HL60R cells by 3-fold,
which is comparable to that of P-gp-expressing cells. To-
gether, these results indicate that the identified peptoids are
potent chemosensitizers with similar efficacy for P-gp and
MRP1.
All selected peptoids contain the chemical groups 2,4-di-
chlorophenylethyl and 3,3-diphenylpropyl at the R2 and R3
positions, suggesting a key role for hydrophobic planar
groups at these positions of the oligomer. The first diversity
position, however, allowed slightly higher chemical diversity,
although fluorophenylethyl groups were preferred. The
abundant presence of hydrophobic planar groups, along with
hydrogen bond acceptors, is consistent with the pharmaco-
phoric properties proposed for P-gp antagonists. This tenet
was further substantiated by the alignment of peptoid
N151212C with the pharmacophoric model generated by Cat-
alyst. However, one hydrogen acceptor was not properly fit-
ted to the pharmacophore, suggesting that compound
N151212C requires structural refinement for improved bind-
ing to P-gp.
A major effort is being devoted to develop nontoxic chemo-
sensitizer drugs that could be used as adjuvants of current
chemotherapy. The unwanted toxicity and side effects asso-
ciated with current chemosensitizers have been attributed to
interference with other cellular mechanisms or high-affinity
blockade of P-gp. Complete pharmacological knockout of P-gp
may lead to increased accumulation of cytostatics in sensitive
Fig. 7. Identified N-trialkylglycines fit onto the pharmacophore model
characteristic of antagonists and substrates of P-gp. N151212C (A) and
tariquidar (B), a potent chemosensitizer of the MDR phenotype (Mistry et
al., 2001), fitted into the pharmacophore hypothesis generated by Cata-
lyst. Pharmacophore contains two hydrophobic regions (cyan), one ring
aromatic (orange), and two hydrogen bond acceptor features (green). For
the sake of clarity, one of the hydrogen bond acceptors that showed no
interactions with N151212C has been removed. C, N151212C aligned
with tariquidar in the pharmacophore model generated by Catalyst. For
clarity, one of the hydrogen bond acceptors that showed no interactions
with N151212C has been removed. The lowest energy conformation of
compounds N151212C and tariquidar are displayed.
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tissues such as brain, as concluded from studies from the
mdr1/ knockout mice (Schinkel et al., 1997; Zhang et al.,
2000). These observations imply that moderate affinity an-
tagonists that partially block the activity of these pumps may
play a relevant therapeutic role by attenuating the side ef-
fects emerging from full blockade of these extrusion pumps.
In addition, moderate-affinity compounds that act with sim-
ilar efficacy on P-gp and MRP1 may have an additional
benefit by tuning down the activity of the major proteins
involved in MDR. Furthermore, this class of compounds may
be valuable for those tumors that coexpress these two drug
efflux pumps. Therefore, the peptoids that we have identified
provide a new pharmacophore scaffold that could be consid-
ered as a pillar for the direct evolution of more active and
safer chemosensitizing drugs. In support of this notion, the
acute, single-dose toxicity of compounds N151212C and
N161212C is 300 mg/kg (i.p.). The structural simplicity of
N-trialkylglycines advantageously makes these peptidomi-
metics susceptible to broad structural manipulation and,
therefore, lead-like property optimization.
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